Login or Register to unlock everything MedSchool has to offer!

Mitotic Inhibitors

Antimetabolites

Topoisomerase Inhibitors

DNA Crosslink Inhibitors

 
 
 

Read More...

 Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Investigational new drugs. 1985 Jun 1;3(2):101-7. Cisplatin. The Lancet. 1982; 319: 374-375. de Weger VA, Beijnen JH, Schellens JH. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel–a review. Anti-cancer drugs. 2014 Jun 1;25(5):488-94. Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. InSeminars in oncology 1992 Apr (Vol. 19, No. 2 Suppl 5, pp. 3-8). Dorr RT. Pharmacology of the taxanes. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1997 Sep 10;17(5P2):96S-104S. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: An Updated Review of the Pharmacokinetic Properties, Clinical Efficacy and Tolerability of a Microemulsion-Based Formulation (Neoral®)su1 in Organ Transplantation. Drugs. 2001;61:1957-2016. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nature Reviews Clinical Oncology. 2009; 6: 638-647. Gellert M, Smith CE, Neville D, Felsenfeld G. Actinomycin binding to DNA: Mechanism and specificity. J Mol Biol. 1965; 11: 445-457. Hortobagyi GN. Anthracyclines in the treatment of cancer. Drugs. 1997 Oct 1;54(4):1-7. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer research. 1991 Apr 15;51(8):2212-22. Kufe DW, Major PP. Studies on the mechanism of action of cytosine arabinoside. Medical and pediatric oncology. 1982 Jan 1;10(S1):49-67. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer. 2003 May 1;3(5):330-8. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47: 119–125. McAlpine D, Johnstone BM. The ototoxic mechanism of cisplatin. Hear Res. 1990; 47: 191-203. Mini E, Nobili SF, Caciagli BF, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Annals of Oncology. 2006 May 1;17(suppl 5):v7-12. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. InSeminars in oncology 1996 Oct (Vol. 23, No. 5 Suppl 10, pp. 3-15). Rivory LP. New drugs for colorectal cancer–mechanisms of action. Australian Prescriber. 2002;25(5). Sakai H, Sagara A, Arakawa K, et al. Mechanisms of cisplatin-induced muscle atrophy. Toxicol Appl Pharmacol. 2014; 278: 190. Segal R, Yaron M, Tartakovsky B. Methotrexate: Mechanism of action in rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 1990 Dec; 20(3): 190-200. Slevin ML. The clinical pharmacology of etoposide. Cancer. 1991 Jan 1;67(S1):319-29. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and genomics 2011; 21(7); 440. Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anti-cancer drugs. 1990 Oct 1;1(1):5-14. Wagner A, Hempel G, Boos J. Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. Anti-cancer drugs. 1997 Jun 1;8(5):419-31. Walko CM, Lindley C. Capecitabine: a review. Clinical therapeutics. 2005 Jan 31;27(1):23-44. Zamble DB, Lippard SJ. Biological mechanisms of cisplatin cytotoxicity. J Inorg Biochem. 1997; 67: 141-141. Zhou XJ, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs. 1992 Nov 1;44(4):1-6.
Feedback